In the increasingly crowded AI for drug discovery sector, it’s tough to tell which startups are set to drive clinical outcomes, and which are still years away from the lab. One way of doing so is seeing which ones major pharma companies trust to partner with.
Today, Immunai is doing just that by announcing a major expansion of its collaboration with AstraZeneca,
The startup is building what it calls a “map of the immune system,” and under the terms of the new agreement is eligible to receive up to $37.5 million through 2027 to apply its AI-driven insights to AstraZeneca’s oncology pipeline.
The deal isn’t just a cash injection; it’s a strategic deepening of a relationship that began in 2024. While the initial partnership focused on oncology clinical programs, and a 2025 expansion moved into inflammatory bowel disease (IBD), this latest bridge extends the work through the end of 2027.
The Operating System for Immunity
At the heart of the deal is Immunai’s AMICA-OS, an AI operating system that attempts to do for the human immune system what Google Maps did for geography.
Most traditional drug development relies on bulk data, looking at a tissue sample as a whole. Immunai, however, operates at single-cell resolution. By looking at how individual cells behave within the immune system, the company’s foundation models can help pharma companies identify why certain patients respond to a drug while others don’t.
“The fact that AstraZeneca continues to deepen this collaboration is a strong signal for us that the platform is delivering,” Immunai CEO Noam Solomon, Ph.D., said in a press release.
AstraZeneca is using the platform for the heavy lifting of clinical trials: biomarker discovery (finding biological “signs” that a drug is working), patient stratification (identifying which patients should be in a trial), and dose optimization.
Why Big Pharma is Doubling Down
For AstraZeneca, the investment reflects a broader industry shift toward mechanistically informed AI. Rather than just using AI to screen for new molecules, they are using it to understand the biological why behind a drug’s performance.
“We are continuously investing in frontier AI models and solutions to inform clinical development decisions,” said Jorge Reis-Filho, Chief of AI for Science Innovation at AstraZeneca. He noted that the collaboration reflects a conviction that AI can fundamentally “improve patient outcomes.”
The Big Picture
To date, Immunai has raised nearly $270 million in funding and grown its team to over 170 experts across biology, AI, and medicine.
While many AI startups struggle to move past the proof of concept phase with legacy pharmaceutical giants, Immunai appears to be successfully embedding itself into the R&D workflow. If they can continue to prove that single-cell data leads to higher success rates in clinical trials, the most expensive part of the drug-making process, $37.5 million might look like a bargain for AstraZeneca in the long run.
